Dispensary observation of patients with low-risk group of neuroblastoma (Except for stage 4S)
https://doi.org/10.17650/2311-1267-2015-1-101-106
Abstract
This paper presents a protocol of dispensary observation of patients with neuroblastoma of low-risk group. Development of the observation protocol is based on the experience of German group on treatment of neurogenic tumors (protocol NB-2004) and published data on the prognosis and incidence of recurrence in this cohort of patients.
Aspects of distant organ toxicity for patients receiving chemotherapy due to availability of life-threatening symptoms at diagnosis and further observation are covered. In this article we do not touch upon the subject of observation of patients with stage 4S disease, as this group of patients requires a more detailed discussion.
About the Authors
D. Yu. Kachanov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
T. V. Shamanskaya
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
E. S. Andreev
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
G. M. Muftahova
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
G. A. Novichkova
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
S. R. Varfolomeeva
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
References
1. Goodman M.S., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G. et al. (eds.). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. NIH Pub. No. 99–4649. Bethesda, MD, 1999. Pp. 65–72.
2. Spix C., Pastore G., Sankila R. et al. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91.
3. Shusterman S., George R.E. Neuroblastoma. In Oncology of Infancy and Childhood. Orkin S.H., Fisher D.E., Look A.T. et al (eds.). Saunders, 2009. Pp. 509–540.
4. Park J.R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 2008;55(1):97–120.
5. Simon T., Spitz R., Faldum A. et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004; 26(12):791–6.
6. Strother D.R., London W.B., Schmidt M.L. et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children, s Oncology Group study P9641. J Clin Oncol 2012;30(15):1842–8.
7. Woods W.G. Screening for neuroblastoma. In Book: Neuroblastoma. Cheung N.-K., Cohn S. (eds). Springer-Verlag, Berlin, Heidelberg, 2005. Pp. 7–20.
8. Hero B., Simon T., Spitz R. et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008;26(9):1504–10.
9. Garaventa A., Parodi S., De Bernardi B. et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009;45(16):2835–42.
10. de Bernardi B., Mosseri V., Rubie H. et al.; SIOP Europe Neuroblastoma Group. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008;99(7):1027–33.
11. Berthold F., Hero B., Breu H. et al. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol 1996;7(2):183–7. Guidelines Children, s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers, Version 4.0. Monrovia, CA: Children, s Oncology Group; October 2013; Available on-line: www.survivorshipguidelines.org. Access 01.02.2014.
Review
For citations:
Kachanov D.Yu., Shamanskaya T.V., Andreev E.S., Muftahova G.M., Novichkova G.A., Varfolomeeva S.R. Dispensary observation of patients with low-risk group of neuroblastoma (Except for stage 4S). Russian Journal of Pediatric Hematology and Oncology. 2015;2(1):101-106. (In Russ.) https://doi.org/10.17650/2311-1267-2015-1-101-106
Views:
1134
Email this article 